ANGO's Q4 FY26 revenues rise 8% as Med Tech surges, while its adjusted loss beats estimates and FY27 sales guidance tops consensus.

AngioDynamics Inc (ANGO) reports robust revenue increases driven by MedTech and NanoKnife segments, despite facing net losses and competitive market pressures.

AngioDynamics (NASDAQ:ANGO) reported higher fiscal fourth-quarter and full-year revenue, driven by continued growth in its med tech portfolio, while management said the company remains focused on balancing investment in clinical programs with profitability and cash generation. On the company’s fisc

AngioDynamics (ANGO) delivered earnings and revenue surprises of +36.36% and +7.61%, respectively, for the quarter ended May 2026. Do the numbers hold clues to what lies ahead for the stock?

AngioDynamics Inc. (NASDAQ:ANGO) delivered stronger-than-expected fourth-quarter results on Tuesday, beating Wall Street forecasts for both revenue and adjusted earnings while issuing an upbeat sales outlook for fiscal 2027.

LATHAM, N.Y. (AP) — AngioDynamics Inc. (ANGO) on Tuesday reported a loss of $11.4 million in its fiscal fourth quarter. On a per-share basis, the Latham, New York-based company said it had a loss of 27 cents. For the year, the company reported that its loss widened to $36.7 million, or 88 cents per share.